Articles by Editor

Achieving the standard of care, no matter the language or disability.

ANN ARBOR, Mich., July 19, 2023 (Newswire.com)
–
Vidatak is proud to announce the latest feature, Talk-to-Translate, has just been added to VidaTalk to better ensure providers can deliver equitable care to patients with communication barriers and disabilities on a 24/7 basis.

VidaTalk is a first-in-kind, multilingual, point-of-care communication solution for patients with speech, hearing and language barriers. This customizable app for patients and providers includes picture-option communication selections that generate bilingual text and audio output when selections are made across 40 language profiles, relaxation videos, therapeutic restorative music, video and audio interpreter access, talk-to-text, and now, talk-to-translate. The new talk-to-translate feature released today ensures that even under the rarest circumstances, patients and providers will be able to understand one another.

Language barriers pose significant challenges in healthcare where effective and timely communication is vital. While in-person and remote video and telephonic interpreter services provide this essential service as the standard of care, they simply are not always feasible or available with every patient encounter, especially for languages spoken with lower frequency. 

With delayed or absent access to interpreters, providers find themselves unable to communicate with or understand their patients. This communication gap exposes patients to significant risk of harm, misdiagnosis, delayed diagnosis, and delayed or absent treatment. While for complex conversations, such as discharge instructions, Google Translate has been shown to be unreliable, in certain circumstances, it may be necessary.

“As VidaTalk continues to harness the technologies that drive equitable experiences for vulnerable patient populations, it is essential for hospitals to consider what their standard of care actually delivers with respect to a real-time multilingual experience and a human-centered approach to care.” – Dr. Patak, CEO of Vidatak

Vidatak’s Chief Experience Officer, Lisa Spencer, shares a personal experience she had with a loved one: “My family member could not communicate his needs and symptoms. It was frustrating and heartbreaking for everyone. I’m not alone. Every hospital is caring for patients with speech, hearing and language barriers. For patients that don’t speak the same language as their caregivers, using certified interpreters is the gold standard; but, when no one with language services is available, patients still need to communicate. That’s why I’m so excited that VidaTalk now has this new talk-to-translate feature. No one deserves to suffer or be in pain for hours, or even an entire weekend, simply because an interpreter can’t be reached.”

By ensuring that multilingual communication can occur in real time at the point of care, VidaTalk validates the highest standard of care, establishing a mechanism for effective communication for patients who have speech, hearing or language barriers. This vital connection can alleviate patient distress, enhance trust, and contribute to a more positive healthcare experience. When patients feel understood and supported, they are more likely to actively engage in their own healthcare journey, leading to better compliance, faster recovery, and enhanced overall well-being.

VidaTalk has revolutionized the healthcare experience for hospitalized patients who cannot speak, cannot hear, or have limited English proficiency. “As VidaTalk continues to harness the technologies that drive equitable experiences for vulnerable patient populations, it is essential for hospitals to consider what their standard of care actually delivers with respect to a real-time multilingual experience and a human-centered approach to care,” states Dr. Patak, CEO of Vidatak.

Contact Information:

Lance Patak

CEO

[email protected]

(323) 697-9906

Lisa Spencer

Chief Experience Officer

[email protected]

‭(425) 247-4007‬

Related Files
Adults with Communication Disabilities Experience Poorer Health and Healthcare Outcomes Compared to Persons Without Communicatio
Giving Voice- Nurse-Patient Communication in the Intensive Care Unit.pdf

Related Images

Original Source:

VidaTalk’s Talk-to-Translate Feature Will Have a Transformative Impact on Hospitalized Patients With Language Barriers

The post VidaTalk’s Talk-to-Translate Feature Will Have a Transformative Impact on Hospitalized Patients With Language Barriers appeared first on AESTHETIC NEWS.

Hygiene, heat and hydration, common-sense approaches to managing dry eye

Bruder Healthcare Bruder Healthcare

ATLA…

The post In Support of Dry Eye Awareness Month, Bruder Healthcare Recommends Three-Part Solution for Dry Eyes appeared first on AESTHETIC NEWS.

Hospital Systems Connecting with Blockchain – Illustration

LOUISVILLE, Ky., July 18, 2023 (Newswire.com)
–
Baptist Health, Kentucky’s largest health sy…

The post Baptist Health Partners With MediLedger to Ensure Correct Pricing via Contract Management appeared first on AESTHETIC NEWS.

The company pioneered and received clearance earlier this year on the world’s first 3D printed, fully interconnected porous PEEK interbody.

HUNTSVILLE, Ala., July 18, 2023 (Newswire.com)
–
Curiteva, a privately held technology and manufacturing company based in Huntsville, AL announces the commercial launch of its Inspire Porous PEEK HA^FUSE Cervical Interbody System. 

The company pioneered and received clearance earlier this year on the world’s first 3D printed, fully interconnected porous PEEK interbody. This extraordinary advancement in additive manufacturing of polymers creates a new classification of interbody fusion devices with optimal characteristics for bony healing.

“We are very pleased with the positive surgeon feedback we received during our limited release in April. Now with full commercialization, the team is excited to see continued adoption of our novel 3D printed porous PEEK implant with HA^FUSE Technology,” stated Mark Mohlman, EVP. “This launch is just the beginning as we continue to develop our additional lumbar portfolio scheduled for launch in 2024.”

The Inspire platform is manufactured with a proprietary, patented Fused Filament Fabrication 3D printer designed, programmed, and built by Curiteva. This ground-breaking additive process produces a fully interconnected and integrated porous structure traversing the entire implant to promote osseointegration, improve radiographic assessment, and deliver superior biomechanics. The first-to-market combination of the HA^FUSE nanotechnology surface treatment and novel porous PEEK structure creates a hydrophilic, bioactive environment for cell attachment, proliferation, and healing in pre-clinical animal and in vitro studies.

“Curiteva received FDA clearance in February, initiated our alpha release in April and scaled to a commercial launch in July. I am proud of the entire Curiteva team for another milestone achievement and grateful to our surgeons and distributors for their patience and support,” commented CEO Mike English. 

The Inspire technology will be featured at the NASS meeting later this year. 

Curiteva is a privately held technology and manufacturing company dedicated to advancing spine surgery and improving clinical outcomes by partnering with providers and suppliers to deliver innovative and intuitive implant systems to the market. Our business is founded on a commitment to building world-class manufacturing, accelerating research and development, maintaining lean operational discipline, and delivering novel technology to meet the evolving needs of our customers and the patients they serve. 

Contact Information:

Kristen Kyzer

Director of Business Development

[email protected]

256.213.1057

Original Source:

Curiteva Announces World’s First 3D Printed PEEK Device With Regulatory Clearance Reaches Full Commercial Launch in the United States

The post Curiteva Announces World’s First 3D Printed PEEK Device With Regulatory Clearance Reaches Full Commercial Launch in the United States appeared first on AESTHETIC NEWS.

FemAid Device Offers Relief from Female Incontinence

FemAid Test Stand View of FemAid pressure testing stand.

LOS…

The post FemAid Addresses Female Incontinence appeared first on AESTHETIC NEWS.

A Leader in Developing Cutting-Edge Hospital Applications, M2 Information Systems Launches IRIS Family Messaging to Help Streamline Communication & Foster Stronger Connections Between Patients, Their Families & Healthc…

The post M2 Information Systems Launches Revolutionary IRIS Family Messaging: Reinventing Communication in Healthcare Settings appeared first on AESTHETIC NEWS.

“With nearly half of Medicare-eligible women having gone years without receiving a mammogram,” noted Bob Still, the Executive Director of RBMA, “it is unconscionable for Congress to again decrease Medicare reimbursement for providers.”

FAIRFAX, Va., July 17, 2023 (Newswire.com)
–
The Radiology Business Management Association’s Radiology Patient Action Network (RPAN) urges Congress and the U.S. Center for Medicare and Medicaid Services (CMS) to safeguard Medicare funding for physicians in light of proposed cuts in payments to providers under the proposed 2024 Medicare Physician Fee Schedule (MPFS).

“With nearly half of Medicare-eligible women having gone years without receiving a mammogram, it is unconscionable for Congress to again decrease Medicare reimbursement for providers, particularly those who perform screenings and procedures that aid in detecting and treating life-threatening diseases,” said Bob Still, the Executive Director of RBMA. “These cruel cuts not only hinder access to healthcare for Medicare recipients, but they could harm Medicaid patients too since many states link Medicaid to Medicare rates. The continued cycle of reimbursement cuts will further reduce access, worsen health disparities, and cost the country an incalculable amount of money over the long term. Congress must take action to halt these substantial cuts to independent Medicare doctors and their patients.”

RPAN strongly urges Congress to pass H.R. 2474 on behalf of healthcare providers and patients nationwide. This legislation marks the beginning of a comprehensive reform to Medicare, including an adjustment for inflationary factors. These reforms mirror recommendations from MedPAC and other groups.

“While independent providers with high Medicare volumes face significant reductions in reimbursement, other provider types continue receiving inflationary updates and reimbursement increases,” explained Still. “This growing disparity in reimbursement will only foster more consolidation among healthcare providers, aggravating inequities between provider types, and ultimately limiting patient access to care.”

Contact Information:

Will Sweet

RBMA

[email protected]

Original Source:

Radiology Patient Action Network Urges Congress and CMS to Prevent ‘Cruel’ Cuts to Medicare Access

The post Radiology Patient Action Network Urges Congress and CMS to Prevent ‘Cruel’ Cuts to Medicare Access appeared first on AESTHETIC NEWS.

Five Star Orthodontic Laboratory & Supply, Inc. has been servicing the Orthodontic community for over 30 years. They will be using the In Hand Dental platform to add strategic value to their Tri-Aligners product line a…

The post Remote Monitoring and Teledentistry App In Hand Dental Partners With Five Star Orthodontic Laboratory & Supply, Inc. appeared first on AESTHETIC NEWS.

ST. PETERSBURG, Fla., July 14, 2023 (Newswire.com)
–
GOBEL, the world’s leading consulting and technology firm working exclusively for healthcare philanthropy…

BUFFALO, N.Y., July 14, 2023 (Newswire.com)
–
 POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650). EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO’s spontaneous-nanoliposome antigen particle (SNAP) technology.

The phase 3 trial of EuCorVac-19 was conducted in the Philippines in approximately 2,600 adults (NCT05572879). EuCorVac-19 demonstrated superior antibody immunogenicity compared to a World Health Organization Emergency Use Authorized adenoviral vector vaccine, thereby meeting the primary endpoint of the phase 3 trial.

The formation of neutralizing antibodies, which prevent COVID-19 infection, was more than twice as high in EuCorVac-19 compared to the control vaccine. EuCorVac-19 exhibited a high serological response rate with neutralizing antibody titers increasing after vaccination. In particular, the neutralizing antibody titers and serum response rates in subjects aged over 65 exceeded those of the control vaccine. In immunogenicity analysis against the Omicron BA.5 strain, EuCorVac-19 induced more than twice the neutralizing antibody titer compared to the control vaccine.

EuCorVac-19’s safety profile was further established in this phase 3 study. EuCorVac-19 showed a slightly lower incidence than the control vaccine of solicited adverse events and there was no difference between EuCorVac-19 and the control vaccine in the incidence of unsolicited adverse events.

These results further validate the strength and synergy of POP BIO’s SNAP and EuBiologics’ EuIMT platform technologies used in the EuCorVac-19 vaccine. Further development of booster vaccines, new strain vaccines, and combination vaccines for COVID-19 will be significantly more straightforward in the future. 

“Achieving the completion of this Phase III trial is an enormous milestone for our technologies. These results provide validation towards not only solving this unprecedented global crisis but also provides invaluable support towards our platform’s development, further enabling the creation of new vaccines with tremendous potential to alleviate suffering worldwide,” said POP BIO co-founder Jonathan Smyth.

EuCorVac-19 was already shown to be safe and immunogenic in a Phase I/II clinical trial, the results of which were announced in December 2021. The Philippine Phase 3 trial, conducted since third quarter of 2022, were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the ministry of Health & Welfare, Republic of Korea.

Based on the results of this clinical study, EuBiologics plans to apply for product approval in the Philippines shortly. Later this year, results will become available from a second independent Phase 3 clinical study being carried out in the Democratic Republic of Congo.

About POP Biotechnologies: POP Biotechnologies, Inc. is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The PoP technology, exclusively licensed from the State University of New York Research Foundation (SUNY-RF), was developed by company co-founder Dr. Jonathan Lovell at his academic facilities at The State University of New York at Buffalo (SUNY Buffalo). POP Biotechnologies is currently a resident of the SUNY Buffalo incubator at Baird Research Park.

About POP BIO’s SNAP Technology: POP BIO’s Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of highly immunogenic particle-based vaccines and immunotherapies directed against infectious disease and cancer through the use of a cobalt modified variant of the PoP technology (CoPoP). The SNAP technology enables the seamless generation of stable particle-formation and liposome-display of protein and peptide antigens resulting in substantial improvements in immune responses.

About EuBiologics: EuBiologics is a South Korean Biotechnology company that is advancing the EuCorVac-19 COVID-19 vaccine and other vaccine products. EuBiologics has two main animal-based bioreactors (1,000L) to produce recombinant protein antigens at Chuncheon Plant 1(C-Plant) and EcML(Monophosphoryl Lipid A) which is adjuvant at Chuncheon Plant 2(V-Plant). The total capacity of the COVID-19 vaccine is currently in the hundreds of millions of doses per year.

About EuBiologics’ EuIMT Technology: EuBioloigcs’ Immune Modulation Technology using genetically engineered Monophosphoryl Lipid A (MLA), called EcML that is a unique TLR4 agonist. EuBiologics has IP protection around EcML and various adjuvant systems including EcML. Eubiologics’ EcML and POP BIO’s SNAP technologies synergize to create ultrapotent next-generation vaccines.

Contact Information:

Jonathan Smyth

President

[email protected]

+13152200087

Original Source:

POP Biotechnologies and EuBiologics’ EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial